Liufeng Medical -B (02675.HK) Listing Time

The IPO is scheduled for December 30-January 5 and is expected to be listed on January 8, 2026.

Fung Medical -B (02675.HK) One Hand Purchase Amount

Starting price 43.24, first order $4367.61

IPO Subscription | Real 0 Interest 0 Handling Fee

2675 IPO | Yufeng Medical - B Active Stock Auction, Surgical Robotics Company Launched on January 8

Futu InformationNewsDecember 30 News, Surgery News December 30 News, Surgical Robotics Company$ ELITE MEDICAL -B (02675.HK) $The announcement was made that the Company intends to offer approximately 27.7222 million shares worldwide at the IPO on December 30-January 5, which is expected to be listed on January 8, 2026.

Fung Medical -B One Hand Purchase $4367.61

Company Profile

Founded in 2017, Yufeng Medical is an advanced surgical robotics company in the Medical Device Industry, specializing in the design, development and manufacturing of surgical robots. The company operates three different brands of products in different stages of development and products in research to harness the market momentum of surgical robotics, including multi-hole microscope surgical robots for microsurgery and single-hole surgical robots for non-surgical procedures, and natural duct surgery robots for non-surgical techniques.

Currently, Reshaptic Medical's product portfolio includes two independently developed core products: Precision Multi-hole Lens Surgical Robotics and Single-Hole Spectroscopic Mechanical Robots. The company's product portfolio includes Precision Vacuum Tube Robotics and non-core products. Precision multiple-hole surgery Robotics is a robotic assistive device for performing microsurgery using robotics, imaging and digital technologies, for applications in gynecology, pediatrics, general surgery and thoracic surgery. Precision Single-Hole Surgical Robotics is a Robotics Assistive Device for Microsurgical Applications through a single small incision or natural canal, for use in gynecology, obstetrics and general surgery.

Financial Overview

Yufeng Medical's revenue increased from RMB48 million for the year ended December 31, 2023 to RMB160 million for the year ended December 31, 2024. For the year ended December 31, 2023, the company's sales cost RMB19.6 million, compared to December 31, 2024, the company's sales cost RMB61.9 million. The Company's income, net of credit, increased by RMB30.2 million for the six months ended June 30, 2024 to RMB149.4 million for the six months ended June 30, 2025.

For the six months ended 30 June 2024, the company generated sales of RMB11.1 million, compared to RMB55.5 million for the six months ended 30 June 2025. However, the Company incurs an Operating Loss for many years during the reporting period. For the years ended December 31, 2024 and the six months ending June 30, 2025, the Company recorded net losses of RMB212.9 million, RMB218.5 million, RMB132.6 million and RMB89.1 million, mainly due to the Company's development support.

Industry Overview

Surgical Robotics Overview Surgical Robotics is a sub-branch of Medical Robotics. Surgical Robotics, Surgeons can enter the inside of the patient's body through remote control and precise operation through micro-incisions. Precision-operating Robotics that help surgeons perform microsurgical microsurgery. The main structures of the surgical robot include a patient surgical platform, a mechanical machine on the immediate patient's periphery, and a physician control tower (providing the surgeon to operate the mechanical machinery and/or flight guidance system) through the provision of 3D models to assist the surgeon in planning the surgical solution in advance and instruct the outpatient in real time. IMAGING SYSTEM (INCLUDING AN IMAGE SCREEN WITH A SURGICAL AID FOR REAL-TIME MONITORING OF SURGERY).

The inpatient efficiency of surgical robotics is under pressure at the same time as various key technologies, the demand for surgical robotics is constantly increasing, and more factors are being driven by the mutual drive, so the global surgical robotics market model continues to grow rapidly. The global market model for Surgical Robotics grew by $7.7 billion in 2019 to $21.2 billion in 2024, compounded growth of 22.4% in the year, the global market model is forecast to reach $84.2 billion in 2033, and compound growth of 16.6% year-on-year, indicating a huge dive in the Surgical Robotics market.

Surgical Robotics, the largest market in surgical robotics, is a surgical robot that can be applied to a wide range of surgical specialists in urology, obstetrics, general surgery and thoracic surgery. The following chart shows the historical and projected growth of the global Surgical Robotics market and the segmented markets by surgical application.

Cornerstone Investors

The cornerstone investor has agreed to sell certain shares, subject to certain conditions, for a total subscription price of $75 million, to be purchased at the offering price. Cornerstone investors include:

Abu Dhabi Investment AuthorityUBS Asset Management (Singapore) LtdOrbiMed Genesis Master Fund, L.P. Huang River Investment Limited; LYFE Capital Fund IV (Dragon), L.P.

Funding Purposes

In terms of financing, Fengfeng Medical will receive a net global sales revenue of HK$1116.6 million. (The resale super sale option is not exercised at the sale price of HK$43.24). Based on the solicitation of shares, Smartwatch will use global sales pool funds for the following purposes:

Approximately 42.0% will be allocated to the ongoing and planned development of the core product, approximately 20.0% will be used for commercialization of our core product, about 10.0% will be used for expanding production, approximately 8.0% will be allocated to other products and products under investigation, approximately 10.0% of the total proceeds Approximately 10.0% of the net proceeds will be used for operating funds and general corporate use in strategic acquisitions, investments or cooperation in the Surgical Robotics Industry and related sectors.